This recognizes an internal epitope of human BCRP (70 kDa), a transmembrane half-transporter. The does not cross-react with the human MDR1, MRP1, and MRP2 gene products.
Note: Not all species have been tested for usefulness with this product. Only those species listed have been tested. We cannot make any guarantees about additional reactivities which may or may not occur.
Fusion protein composed of E. Coli maltose binding protein and BCRP peptide [126 amino acids, 271-396 AA of BCRP.
Localization:
Plasma membrane; integral membrane protein
Marker:
Hematopoietic Stem Cell Marker
Species Reactivity:
Cross-reacts with Human. Not yet tested in other species.
Applications:
Uses:
ICC: Using immunocytochemistry on acetone-fixed, frozen cytospin preparations. IHC: Using immunohistochemistry on acetone-fixed, frozen sections using rabbit anti-mouse IgG and a APAAP complex. The antibody can be used on formalin-fixed, paraffinembedded human tissues and tumors after pretreatment with 10 mM citric acid, pH 6.0, for 20 minutes. WB: Use at assay dependant dilution.
Dilutions:
Western Blot ,
Immunocytochemistry 1/20 to 1/50 ,
Immunohistochemistry-Paraffin 1/20-1/40,
Immunohistochemistry-Frozen 1/20-1/40,
Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.
Buffer:
Supplied in serum-free medium containing 0.7% BSA
Preservative:
0.1% Sodium Azide
Limitations:
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Products are guaranteed for 6 months from date of receipt, except for peptides and proteins which are guaranteed for 3 months.
Tumor cells may display a multidrug resistant phenotype by overexpression of ATP-binding cassette transporters such as multidrug resistance (MDRI) p-glycoprotein, multidrug resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP). Tumor cells can be intrinsically resistant to drugs or they can acquire resistance to structurally and functionally unrelated drugs on drug exposure. This phenomenon is known as multidrug resistance (MDR). In human tumor cells, several transporter
proteins can be involved in MDR. These proteins, MDR1 P-gp (ABCB1), MRP1 (ABCC1), MRP2 (ABCC2), MRP3 (ABCC3), and BCRP (ABCG2), belong to the ABC transporter family. They act as efflux pumps, which result in decreased intracellular concentrations of cytotoxic drugs.
BCRP is a recently discovered half-transporter that probably acts as a homo- or heterodimer in transporting cytotoxic agents. The transporter molecule is capable of transporting several anticancer drugs but has thus far been found mainly in MX-resistant cell lines.
Ejendal, K., et al. The nature of amino acid 482 of human ABCG2 affects substrate transport ATP hydrolysis but not substrate binding. Protein Sci., 15: 1597-1607, Jul 2006.